Key facts
- It has raised $5.6M across 1 recorded rounds; the latest was Seed Round ($529K) in Jan 2024.
- Notable investors include Novatio Ventures.
- ImmVue Therapeutics has filed 2 Form Ds with the SEC, most recently Apr 2024 ($529K sold to 3 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ImmVue Therapeutics
Funding rounds
1 roundsAbout ImmVue Therapeutics
Developer of a small-molecule-based therapeutic platform designed to modulate cell activities through allosteric modulation. The company's platform offers allosteric agonists and inhibitors of interleukin-2-inducible T-cell kinase and Bruton's tyrosine kinase, enabling patients with enhanced immune response against treatment-resistant cancers.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2017
- Employees
- 6
- Website
- immvue.com/
- Ownership
- Privately Held (backing)
ImmVue Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ImmVue Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ImmVue Therapeutics in its N-PORT filings yet. We sweep new filings monthly.